Structural Analysis of a New Cytotoxic Demethylated Analogue of Neo-N-methylsansalvamide with a Different Peptide Sequence Produced by Fusarium solani Isolated from Potato
- Authors
- Lee, Hee-Seok; Lee, Chan
- Issue Date
- May-2012
- Publisher
- AMER CHEMICAL SOC
- Keywords
- Neosansalvamide; cyclic pentadepsipeptide; Fusarium solani; cytotoxic activity
- Citation
- JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, v.60, no.17, pp 4342 - 4347
- Pages
- 6
- Journal Title
- JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY
- Volume
- 60
- Number
- 17
- Start Page
- 4342
- End Page
- 4347
- URI
- https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/20325
- DOI
- 10.1021/jf205217v
- ISSN
- 0021-8561
1520-5118
- Abstract
- A novel cytotoxic cyclic pentadepsipeptide, neosansalvamide, was produced by Fusarium solani KCCM90040 isolated from Fusarium-contaminated potato in Korea. The molecular formula of neosansalvamide was analyzed as C32H50N4O6 by electrospray ionization tandem mass spectrometry and combined structural analysis. The one- and two-dimensional nuclear magnetic resonance and absolute configuration of amino acid spectral data allowed for the resolution of cyclic five subunits linked in the following order: (S)-leucic acid, two L-leucine, L-valine, and L-phenylalanine, and this sequence shows a molecular structure as a new demethylated analogue of neo-N-methylsansalvamide but having a different peptide sequence. The cytotoxic effects of neosansalvamide were investigated by sulforhodamine B bioassay on four human cancer cell lines. The IC50 value of neosansalvamide required to inhibit cell growth in vitro by 50% for A549 (lung cancer), SK-OV-3 (ovarian cancer), SK-MEL-2 (skin melanoma), and MES-SA (uterine sarcoma) cell lines were 11.70 +/- 0.55, 10.38 +/- 0.64, 13.99 +/- 1.32, and 11.75 +/- 0.13 mu M, respectively (mean +/- standard error).
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Graduate School > ETC > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.